contd. cl 1

R^3 and R^4	are each, independently of one another, H or A,
X	is R^5, R^6 or R^7 monosubstituted by R^8,
R^5	is linear or branched alkylene having 1-10 carbon atoms, in which one or two CH_2 groups may be replaced by -CH=CH- groups, O, S or SO,
R^6	is cycloalkyl or cycloalkylalkylene having 5-12 carbon atoms,
R^7	is phenyl or phenylmethyl,
R^8	is COOH, COOA, $CONH_2$, CONHA, $CON(A)_2$ or CN,
A	is alkyl having from 1 to 6 carbon atoms, and
Hal	is F, Cl, Br or I,

Sch B1

or a physiologically acceptable salt or solvate thereof.

2. (Amended) A compound of the formula I according to Claim 1

(a) 5-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-5-yl]pentanoic acid;

(b) 4-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-5-yl]benzoic acid;

(c) 4-[7-(3,4-methylene[-]dioxy[-]benzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-5-yl]butyric acid;

(d) 5-[7-(benzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-5-yl]pentanoic acid;

(e) [7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-5-ylmethoxy]acetic acid;

or a physiologically acceptable salt or solvate thereof.

3. (Amended) A process for the preparation

of a compound of the formula I according to Claim 1 and salts thereof,

comprising reacting

a) a compound of the formula II



II

in which

R^3, R^4 and X are as defined in Claim 1,
and L is Cl, Br, OH, SCH_3 or a reactive esterified OH group,

with a compound of the formula III



III

in which

R^1 and R^2 are as defined above,

or

b) converting a radical X in a compound of the formula I into another radical X by hydrolysing an ester group to a COOH group or converting a COOH group into an amide or into a cyano group

and/or converting a compound of the formula I into one of its salts.

4. (Amended) A process for the preparation of a pharmaceutical preparation, comprising converting a compound of the formula I according to Claim 1 and/or one of its physiologically acceptable salts and solvates into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or solvent.

5. (Amended) A pharmaceutical preparation, comprising at least one compound of the formula I according to Claim 1 and/or a physiologically acceptable salt or solvate thereof.

6. (Amended) A compound of the formula I according to Claim 1 and physiologically acceptable salt or solvate thereof for combating a disorder of the cardiovascular system and for the treatment and/or therapy of potency disorders.

8. (Amended) Use of compounds of the formula I according to Claim 1 and/or their physiologically acceptable salts and solvates for the preparation of a medicament.

9. (Amended) A method of treating a disease of the cardiovascular system or a potency disorder, comprising administering a compound of claim 1.